Mar

    Product Hopping, Product Withdrawal

    12 PM EDT

    Two recent cases, New York v. Actavis PLC and In re: Suboxone Antitrust Litigation address monopolization claims related to “product hopping” – the phenomenon where a branded pharmaceutical company tries to convert patients from a branded drug facing patent expiration to a newer version with different attributes that remain patented. This program will bring together leading litigators from both sides of these issues to discuss when product hopping raises antitrust issues and how courts should address them.

    Moderator: 

    * Nicholas Widnell, Boies, Schiller & Flexner LLP

    Speakers:

    * Mark A. Ford, WimerHale
    * Elinor Hoffman, New York State Office of the Attorney General
    * Mark R. Lentz, Jones Day
    * Steven Shadowen, Hilliard & Shadowen LLP

    Attending In Person?

    Location:

    Jones Day
    51 Louisiana Avenue, N.W.
    Washington, DC 20001


    *Please note that program materials are only available to registrants and are not to be further distributed.*

    FREE:  Antitrust Section Members, Government, Nonprofit Employees and Students
    $25.00:  Other Non-Members

    Learn about Section Membership or call 800-285-2221 to join with source code:  RAT14IP25.  Instructions for accessing the live program will be provided in a confirmation email.  For this and all upcoming events visit:  http://AmBar.org/ATEvents.

    CLE
    The ABA is not seeking CLE credit for this program.

    Audio Archive
    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     

     

     

     


     

    $25
    NON-MEMBERS
    $10
    MEMBERS
    $0
    SECTION MEMBERS
    Register Now *Additional discounts may apply at checkout

    Log In to view your rate

    Product Hopping, Product Withdrawal

    Event Details

    Format

    Teleconference

    Date

    Mar 13, 2015

    2015-03-13T12:00:00-04:00 2015-03-13T13:30:00-04:00 Product Hopping, Product Withdrawal

    Two recent cases, New York v. Actavis PLC and In re: Suboxone Antitrust Litigation address monopolization claims related to “product hopping” – the phenomenon where a branded pharmaceutical company tries to convert patients from a branded drug facing patent expiration to a newer version with different attributes that remain patented. This program will bring together leading litigators from both sides of these issues to discuss when product hopping raises antitrust issues and how courts should address them.

    Moderator: 

    * Nicholas Widnell, Boies, Schiller & Flexner LLP

    Speakers:

    * Mark A. Ford, WimerHale
    * Elinor Hoffman, New York State Office of the Attorney General
    * Mark R. Lentz, Jones Day
    * Steven Shadowen, Hilliard & Shadowen LLP

    Attending In Person?

    Location:

    Jones Day
    51 Louisiana Avenue, N.W.
    Washington, DC 20001


    *Please note that program materials are only available to registrants and are not to be further distributed.*

    FREE:  Antitrust Section Members, Government, Nonprofit Employees and Students
    $25.00:  Other Non-Members

    Learn about Section Membership or call 800-285-2221 to join with source code:  RAT14IP25.  Instructions for accessing the live program will be provided in a confirmation email.  For this and all upcoming events visit:  http://AmBar.org/ATEvents.

    CLE
    The ABA is not seeking CLE credit for this program.

    Audio Archive
    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     

     

     

     


     

    Sponsors

    Section of Antitrust Law

    Related Products

    Related On-Demand CLE